Posted by Michael Wonder on 17 Jul 2020
NICE backing for Astellas' Xospata
17 July 2020 - NICE has recommended use of Astellas' Xospata (gilteritinib) for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia.
The backing, as outlined in a Final Appraisal Determination, is contingent on a commercial agreement being offered by the company and does not include its use as a maintenance therapy after haematopoietic stem cell transplant.
NICE's recommendation of NHS funding for Xospata is based on data from the Phase III ADMIRAL trial, which showed that patients with relapsed or refractory FLT3 mutation positive acute myeloid leukaemia who received the drug experienced significantly longer overall survival than those who received salvage chemotherapy.
